Cancer Research AACR Legacy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 33, 356-361, February 1, 1973]
© 1973 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clark, J. F.
Right arrow Articles by Weber, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clark, J. F.
Right arrow Articles by Weber, G.

Cyclic Adenosine 3',5'-Monophosphate Phosphodiesterase Activity in Normal, Differentiating, Regenerating, and Neoplastic Liver

Julia F. Clark1, Harold P. Morris2 and George Weber3

Department of Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana 46202 [J. F. C., G. W.], and Department of Biochemistry, Howard University College of Medicine, Washington, D. C. 20001 [H. P. M.]

The behavior of cyclic 3',5'-nucleotide phosphodiesterases [cyclic adenosine 3',5'-monophosphate (cAMP) phosphodiesterases] was compared in normal resting liver, proliferating normal liver (from both developing and partially hepatectomized rats), and neoplastic liver (from both slowly and rapidly growing hepatomas). The enzyme activity was determined in the 100,000 x g supernant fluid at 1 mM cAMP (saturating substrate concentration, "high-Km enzyme") and at 1 µM cAMP (near physiological substrate level, "low-Km enzyme").

The pH curves for liver and the rapidly growing hepatoma 3924A were similar, namely, between pH 6.0 and 9.0. The results of kinetic studies and enzyme assays at 2 cAMP concentrations suggest, but do not yet prove rigorously, that there are present in normal, newborn, and regenerating liver, and in the hepatomas, two cAMP phosphodiesterases, one with a low apparent Km of 2 to 3 µM for cAMP and another with an apparent Km of 100 to 600 µM.

The high-Km phosphodiesterase activity was decreased, in the average cell of the slowly growing hepatoma 47C and the rapidly growing hepatoma 3924A, to 58 and 13%, respectively, of the values of control normal livers. The low-Km phosphodiesterase activity in slowly and rapidly growing hepatomas increased to 185 and 265%, respectively. This alteration in the isozyme pattern of cAMP phosphodiesterase appears to be specific to the neoplastic process, inasmuch as no similar pattern was observed in the rapidly growing differentiating or regenerating liver. The behavior of cAMP phosphodiesterase is in line with the change in pattern observed for the hexokinase and pyruvate kinase systems, and the observations support the view that neoplastic transformation entails a progressive emergence of a reprogramming of gene expression that appears to be linked with tumor growth rate.

1 Recipient of American Cancer Society Institutional Grant IN-46-L.

2 Recipient of USPHS Grant CA-10792.

3 Recipient of USPHS Grant CA-05034 and grants from the American Cancer Society and Damon Runyon Memorial Fund, Inc.

Received 6/30/72. Accepted 10/23/72.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1973 by the American Association for Cancer Research.